Literature DB >> 15476069

Parkinsonism and other movement disorders in outpatients in chronic use of cinnarizine and flunarizine.

Giorgio Fabiani1, Paulo C Pastro, Carolina Froehner.   

Abstract

The purpose of this study is to determine the prevalence and the patterns of movement disorders (MD) in outpatients submitted to the chronic use of cinnarizine (cz) or flunarizine (fz), and to establish the main risk factors for MD development. Over a period of 3 months, data were collected from outpatients who were chronic users of cz or fz in a municipal health institute. A total of 26 outpatients were included and all of them were submitted to a protocol that included DSM-4 diagnosis criteria for drug-induced movement disorders, parkinsonism (PK) and depression. Parkinsonism was diagnosed in 34% of the patients, PK plus akathisia, PK plus akathisia and bucco-linguo-masticatory syndrome (BLMS), isolated BLMS and dystonia were found in 4% patients each. Patients with BLMS had the highest median age and the longest average period in which they used the drugs. The affected group, when compared to the non-affected one, presented with higher rates of depression. This study demonstrates the existence of a direct relationship between the time of use of cz and fz, the age and the prevalence of PK and other MD. It also suggests that these drugs increase the incidence of depression.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15476069     DOI: 10.1590/s0004-282x2004000500008

Source DB:  PubMed          Journal:  Arq Neuropsiquiatr        ISSN: 0004-282X            Impact factor:   1.420


  12 in total

1.  Risk of parkinsonism induced by flunarizine or cinnarizine: a population-based study.

Authors:  Hsiu-Li Lin; Hsiu-Chen Lin; Yuan-Fu Tseng; Shih-Chang Chen; Chien-Yeh Hsu
Journal:  Eur J Clin Pharmacol       Date:  2016-12-16       Impact factor: 2.953

2.  Not all drug-induced parkinsonism are the same: the effect of drug class on motor phenotype.

Authors:  Renato P Munhoz; Delcio Bertucci Filho; Hélio A G Teive
Journal:  Neurol Sci       Date:  2016-11-16       Impact factor: 3.307

Review 3.  Medical and Surgical Treatment for Medication-Induced Tremor: Case Report and Systematic Review.

Authors:  Wardell E Amerika; Saskia van der Gaag; Arne Mosch; Niels A van der Gaag; Carel F E Hoffmann; Rodi Zutt; Johan Marinus; Maria Fiorella Contarino
Journal:  Mov Disord Clin Pract       Date:  2022-05-24

4.  Tardive dystonic syndrome induced by the calcium-channel blocker amlodipine.

Authors:  Dirk Dressler
Journal:  J Neural Transm (Vienna)       Date:  2013-10-30       Impact factor: 3.575

5.  Modulation of visceral nociception, inflammation and gastric mucosal injury by cinnarizine.

Authors:  Omar M E Abdel-Salam
Journal:  Drug Target Insights       Date:  2007-02-12

6.  Effectiveness of a Vestibular Rehabilitation Protocol to Improve the Health-Related Quality of Life and Postural Balance in Patients with Vertigo.

Authors:  Heloísa Freiria Tsukamoto; Viviane de Souza Pinho Costa; Rubens Alexandre da Silva; Gislaine Garcia Pelosi; Luciana Lozza de Moraes Marchiori; Cláudia Regina Sanches Vaz; Karen Barros Parron Fernandes
Journal:  Int Arch Otorhinolaryngol       Date:  2015-05-06

7.  An update on tardive dyskinesia: from phenomenology to treatment.

Authors:  Olga Waln; Joseph Jankovic
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2013-07-12

8.  Tardive akathisia related to the anti-hypertensive agent Sevikar-a case report.

Authors:  Men-Ting Hsieh; Pao-Yen Lin; Chia-Jen Tsai; Chiung-Chih Chang; Yu Lee
Journal:  BMC Pharmacol Toxicol       Date:  2017-06-05       Impact factor: 2.483

9.  Extrapyramidal symptoms after exposure to calcium channel blocker-flunarizine or cinnarizine.

Authors:  Kai-Ming Jhang; Jing-Yang Huang; Oswald Ndi Nfor; Yu-Chun Tung; Wen-Yuan Ku; Chun-Te Lee; Yung-Po Liaw
Journal:  Eur J Clin Pharmacol       Date:  2017-04-06       Impact factor: 2.953

10.  Flunarizine related movement disorders: a nationwide population-based study.

Authors:  Kai-Ming Jhang; Jing-Yang Huang; Oswald Ndi Nfor; Yu-Chun Tung; Wen-Yuan Ku; Cheng-Feng Jan; Yung-Po Liaw
Journal:  Sci Rep       Date:  2019-02-08       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.